01.10.2014 • Newsshale-gasHuntsmanBASF

Huntsman Starts Work on MDI Expansion

Capitalizing on the widening availability of shale-gas derived feedstock, Huntsman is doubling MDI output at Geismar, Louisiana, by 400,000 t/y up to 2018.

In a preliminary step, the company has begun engineering work on an interim expansion to add 50,000 t/y by next year, lifting output to 500,000 t/y. When construction is complete, output capability will rise to 950,000 t/y.

"Shale gas has significantly improved the economics of investing in US facilities and has helped our Geismar facility to establish a strong cost leadership position," said Anthony P. Hankins, president of Huntsman Polyurethanes.

"The planned additional capacity will reinforce this position and establish the plant as a truly global supplier Hankins added.

With demand for MDI-based polyurethanes seen as growing at around 8% annually, Huntsman is investing in new upstream and downstream capacity at several locations."

The company's Geismar site is regarded as the US market's largest integrated producer. It also operates world-scale MDI plants at Rotterdam in the Netherlands, along with its joint venture with BASF at Shanghai, China.

In the first quarter of 2015, the doubling of output at the Shanghai jv to 480,000 is planned to be completed.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.